A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

ClinicalTrials.gov ID: NCT07584226

Public ClinicalTrials.gov record NCT07584226. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.

Study identification

NCT ID: NCT07584226
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Relay Therapeutics, Inc.; Industry
Enrollment: 35 participants

Conditions and interventions

Conditions

Interventions

RLY-8161 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 9, 2026 (Actual)
Primary completion: Dec 30, 2027 (Estimated)
Completion: Dec 31, 2029 (Estimated)
Last update posted: Jul 2, 2026

2026 – 2029

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California, Los Angeles	Los Angeles	California	90095	Recruiting
University of California, San Francisco	San Francisco	California	94143	Recruiting
University of Colorado Hospital	Aurora	Colorado	80045	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
START Midwest, LLC	Grand Rapids	Michigan	49546	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Sarah Cannon Research Institute Oncology Partners	Nashville	Tennessee	37203	Recruiting
NEXT Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07584226, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 2, 2026 · Synced Oct 3, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07584226 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →